• Shanghai Henlius entered a global biosimilars strategic collaboration with Sandoz on Aug. 16, 2026, covering up to 10 mAb or ADC programs.
• Invoiced amount of up to USD 100.5 million is expected in 2026, subject to agreed conditions.
• First batch covers HLX05-N (cetuximab), HLX16 (evolocumab), belimumab; Sandoz receives exclusive commercialization rights outside Greater China.
• Deal economics include up to USD 77 million upfront, up to USD 160 million development milestones, up to USD 77 million commercial milestones.
• Henlius will develop, manufacture, supply; Sandoz will pursue marketing authorizations, commercialization, with a 40% net sales or net profit share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260817-12285867), on August 17, 2026, and is solely responsible for the information contained therein.